Vadastuximab Talirine (SGN-CD33A) Clinical Trials

TrialTitelStudy Record DetailPhaseSponsor/Colaborator
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML PatientsNCT02614560I/IISeattle Genetics
A Safety Study of SGN-CD33A in AML PatientsNCT01902329ISeattle Genetics
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AMLNCT02326584ISeattle Genetics

Drug description of vadastuximab talirine (SGN-CD33A).

Last Editorial Review: February 22, 2016